US Attorney Investigates Sequenom

Sequenom announced in June that the SEC had begun an investigation of the company related its initial announcement in April of data mishandling.

Washington, DC 10/5/09—Sequenom has announced in a filing with the SEC that the US Attorneys Office, FBI and the NASDAQ have each met with the company regarding the results of its independent investigation into the development of a prenatal test for Down syndrome (see IBO 9/30/09). The investigation resulted in the firing of two company executives and three employees. CFO Paul Hawran and Steven Owens, vice president of Commercial Development for Prenatal Diagnostics, resigned.

< | >